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The current wealth of genomic variation data identified at nucleotide level presents the
challenge of understanding by which mechanisms amino acid variation affects cellular pro-
cesses. These effects may manifest as distinct phenotypic differences between individuals or
result in the development of disease. Physical interactions between molecules are the linking
steps underlying most, if not all, cellular processes. Understanding the effects that sequence
variation has on a molecule’s interactions is a key step towards connecting mechanistic
characterization of nonsynonymous variation to phenotype. We present an open access
resource created over 14 years by IMEx database curators, featuring 28,000 annotations
describing the effect of small sequence changes on physical protein interactions. We describe
how this resource was built, the formats in which the data is provided and offer a descriptive
analysis of the data set. The data set is publicly available through the IntAct website and is
enhanced with every monthly release.
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Cells process information and respond to their environmentsthrough dynamic networks of molecular interactions, wherethe nodes are bio-molecules (e.g. proteins, genes, metabo-
lites, miRNAs) and edges represent functional relationships,
including physical protein–protein interactions, transcriptional
regulation, genetic interactions and gene/protein modifications.
Comprehensive and systematic characterization of these networks is
essential to gain a full understanding of complex biological pro-
cesses, of how cells behave in response to specific cues, and of how
individual components of the network contribute to phenotype, in
physiological, pathological or synthetic conditions.
Interactions between molecules may be inherently stable and
essentially irreversible, resulting in the formation of stable mac-
romolecular complexes, or weak transient interactions char-
acterized by a dissociation constant (KD) in the micromolar
range and a lifetime of seconds. A change to a single amino acid
in a protein chain can be enough to disrupt a protein binding site
and may then alter the composition of a sub-network of transient
binders or the formation of a protein complex. A variant leading
to the inactivation of a protein kinase molecule may result in
widespread disruption of post-translational phosphorylation
events and the rewiring of related signalling networks. Many
diseases are caused by specific mutations, and prognosis or
response to treatment is frequently mutation-specific. The study
of how mutations affect molecular interactions is thus of extreme
interest since it can help ascertain the role of specific protein
residues on the universal function of molecular binding. Several
studies1–4 have explored the impact of disease-related variation in
molecular interaction networks, using structural studies and
computational predictions to attempt to both identify variation-
affected interfaces and predict the effect of specific variants on
interactions. These studies suggest that interaction interfaces
contain a significantly higher rate of disease-related variants than
the rest of the molecule and that variant location in these inter-
faces can determine disease specificity.
Despite available high-throughput interaction screening plat-
forms, the experimental validation of these variation effect pre-
dictions on a systems-scale remains a major challenge. However,
these data can be found reported in the literature but difficult to
search and concatenate. Researchers have for many years been
examining the effect of single, or multiple, induced point muta-
tions on both binary and n-ary interactions in small-scale
experiments. Targeted changes to the amino acid sequence of a
protein have been engineered, largely by site-directed mutagen-
esis, with the aim of mimicking known variants5,6, removing
known, or predicted, post-translational modifications7,8, dis-
rupting regions required for protein stability or altering the
properties of protein binding domains9,10, and their effects of the
interaction of interest monitored. It has been the work of the
IMEx Consortium11 to capture such information into a single
data set and thus make it available for researchers to re-use and
re-analyse. IMEx Consortium annotators follow a detailed cura-
tion model, capturing not only full details of the experiment
(including interaction detection method, participant identifica-
tion method and the host organism) but also a description of the
constructs used. This may include the coordinates of deletion
mutants used to derive a minimum binding domain and also the
effect of point mutations. Databases in the Consortium perform
detailed, archival curation of published literature and also receive
pre-publication data through direct submissions. This close col-
laboration with data producers often entails access to unpublished
details in the data, such as experiments reporting mutations that
have no effect on interactions, which enables the capture of added
value for the scientific community.
Here we describe the largest literature-derived data set, to our
knowledge, capturing the effect of sequence changes on
interaction outcome. We discuss how the data set was generated
and how it is maintained by the EMBL-EBI IntAct team. We also
provide an initial analysis of the data set, highlighting its overlap
with genomic variation data, discussing possible biases and
exploring its potential as a benchmarking tool for variant effect
prediction tools.
Results
Data curation and quality control. The IMEx Consortium
databases have been collecting point mutation data for over
14 years, which has resulted in a sizeable data set of almost
28,000 fully annotated events (www.ebi.ac.uk/intact/resources/
datasets#mutationDs). The IMEx resources curate interaction data
into structured database fields, and from there into community
standard interchange formats, and each observation is described
using controlled vocabulary terms. Mutations are mapped to the
underlying protein sequence in UniProtKB and updated in line with
changes to that sequence, to ensure that they stay mapped to the
correct amino acid residue with every proteome release.
In order to make the mutations data set more accessible to the
biomedical scientist, the Consortium has released it in a tab-
delimited format (Table 1 and Supplementary Table 1), which
includes details of the position and the amino acid change of the
mutation, the molecules in the interaction and the effect of the
mutation on the interaction, as well as additional fields containing
contextual information.
Additionally, a data-update pipeline has been specifically
developed to ensure the accuracy of the annotation of mutation
events as interaction participant features (Supplementary Fig-
ure 1). The construction of this pipeline has been made possible
by the creation of specific fields capturing sequence changes in
our recently developed standard format PSI-MI XML3.012. It is
run in coordination with the IntAct database monthly protein
update procedure, which ensures synchronization with Uni-
ProtKB13 and automatically shifts feature positions if there are
changes in referenced protein sequences. The pipeline is applied
to the entire data in the IntAct database (www.ebi.ac.uk/intact),
in which all IMEx data, and also legacy data generated by the
IntAct, MINT, DIP and UniProt curation groups is housed
(see Supplementary Information, sections ‘Initial re-curation of
mutation data in IMEx’ for details on re-annotation and
‘Automated quality control pipeline for mutation entries in
IMEx’ for data-update procedures). The mutation data-update
pipeline will continue to be run in quality control mode with
every release of IntAct to ensure the mutations data set is kept
entirely up-to-date with UniProtKB.
Data set statistics. The full IMEx mutations data set contains
27,868 fully annotated events in which a sequence change has
been experimentally tested in an interaction experiment. All this
information has been manually curated, representing over 33,000
person-hours’ worth of biocurators’ work, and it is continuously
growing with on-going IMEx curation activities. The 4353 pro-
teins annotated come from 297 different species, with over 60% of
the events annotated in human proteins and roughly 90%
annotated in seven main model organisms (see Table 2).
In total, 13,926 interaction evidences are annotated with
differentially reported effects, using the PSI-MI controlled
vocabulary. Most of the effects reported are of a ‘deleterious’
nature, either disrupting (10,976 annotations, 39.3%) or decreas-
ing the interaction (8553 annotations, 30.7%), but there is a
significant number of interactions that are either strengthened
(2256 annotations, 8.1%) or caused (188 annotations, 0.7%) by
the mutation when compared with the wild-type sequence
(Fig. 1a). The data set also includes those mutations that were
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experimentally tested but found to have no effect over the
interaction (3057 annotations, 11%) and ‘undefined’ mutations
that were present in constructs used in the experiment but where
the comparison with the wild type reference is either absent or
not possible (2838 annotations, 10.2%). It is important to note
that the ‘causing’ and ‘no effect’ mutation effect categories have
been only recently adopted into the controlled vocabulary and
captured by the biocurators, so they have a much lower number
of annotations and are not directly comparable with the other
categories.
Protein–protein interaction (PPI) experiments reporting this
type of data have been steadily increasing in the last 20 years, with
over 4100 publications containing data pertaining to mutated
protein sequences curated by the IMEx Consortium. However,
the fraction of PPIs in which a mutated version of a protein has
been reported remains relatively low (Fig. 1b). The majority of the
interactions where a mutated protein was involved were detected
using either affinity chromatography-related methods (such as
co-immunoprecipitations or pull-downs) or by complementation
assays based on transcriptional reporters, mainly variations of the
yeast two-hybrid method (see Fig. 1c). Most of our data set comes
from the curation of small-scale papers each reporting only a few
mutations (Fig. 1d). Around 99% of the publications (4173)
contain less than 100 mutation annotations and represent 80% of
the annotations (22,218). Only 8 publications contain over 100
annotations, with one of them describing over 4000 events, a
study in which the authors systematically tested large numbers of
variants and their effect on interactions5. Recording large-scale
data sets such as this one has been enabled by the development of
the flexible PSI-MI XML3.0 format cited above.
Currently, the only resources that represent the impact of
amino acid substitutions on binding events are the SKEMPI 2.0
database14, UniProtKB and IMEx Consortium member databases
through IntAct (see Table 3 for a detailed comparison). Of these
resources, IMEx is the biggest and the only one that can provide
easily accessible, systematically described, up-to-date annotations.
UniProtKB mutagenesis annotations record whether a change in
sequence affects an interaction, but the experimental context is
not captured and the effects are described in a semi free-text field
that is difficult to parse. SKEMPI offers a detailed overview of
sequence change effects on binding derived from in vitro
experiments, recording changes in affinity and other kinetic
parameters for protein complexes with available structural data in
the Protein Data Bank (PDB)15. Only very specific interaction
detection methods, using purified proteins, are considered, which
limits its scope.
Table 1 Overview of the IMEx mutations data set downloadable flat file
Feature
AC
Feature
short label
Feature
range(s)
Original
sequence
Resulting
sequence
Feature type Feature annotations Affected
protein AC &
detailsa
Interaction
participants &
detailsa
EBI-
10828532
p.
Arg725Glu
725–725 R E mutation
(MI:0118)
MI:0612 (comment): Disrupts
association with VPS33A and
decreases association of VPS18
See
Supplementary
Table 1
See
Supplementary
Table 1
EBI-
985220
p.Ile114Gly 114–114 I G mutation
increasing
(MI:0382)
“ “
EBI-
4370347
p.
[Asn31His;
Ala60Val]
31–31 D H mutation
increasing
(MI:0382)
- (kd): 11e-9M “ “
EBI-
4370347
p.
[Asn31His;
Ala60Val]
60–60 A V mutation
increasing
(MI:0382)
- (kd): 11e-9M “ “
EBI-
10688294
p.Thr2Ala 2–2 T A mutation
decreasing
rate(MI:1130)
“ “
EBI-
9635600
p.
Cys_Ser215-
216Ala_Ala
215–216 CS AA mutation
disrupting
(MI:0573)
“ “
Each mutation annotation is identified with a unique accession (‘Feature AC’) and is described with an HGVS-compliant short label (‘Feature short label’), plus sequence coordinates and amino acid
replacement details (‘Feature range(s)’, ‘Original sequence’, ‘Resulting sequence’). The effect the mutation has on the interactions is listed using the PSI-MI controlled vocabulary (‘Feature type’). Each
line in the file represents a single continuous section of sequence affected, with mutations spread in multiple positions represented in several lines and sharing the same ‘Feature AC’. Annotations for
complex effects that cannot be captured via PSI-MI CV and kinetic parameters are also recorded when available (‘Feature annotations’). aThese are placeholders for additional columns containing
information about the affected proteins and interactions. These are available in the fully expanded version of this table in Supplementary Table 1
Table 2 Summary statistics per organism
Organism Annotated events Sequence changes Affected proteins Affected interactions Source publications
Homo sapiens 16,861 7955 2095 8268 2219
Mus musculus 2236 1406 482 1248 509
Saccharomyces cerevisiae 2029 1144 363 1069 326
Arabidopsis thaliana 1172 546 187 590 189
E. coli (strain K12) 979 614 143 374 148
Rattus norvegicus 562 354 142 341 160
Drosophila melanogaster 359 232 100 214 92
Others (290 species) 3670 2396 841 1951 855
Totals 27,868 14,647 4353 13,926 4182
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-07709-6 ARTICLE
NATURE COMMUNICATIONS |           (2019) 10:10 | https://doi.org/10.1038/s41467-018-07709-6 | www.nature.com/naturecommunications 3
There is limited overlap between these resources, with only 4
publications and 44 reported sequence changes found in all three.
We manually assessed the consistency of the annotations for
these 4 publications and found a number of inconsistencies
caused by different curation practices. Most notably, SKEMPI 2.0
reports mutation coordinates using the chains as annotated in
PDB, which often differs from the actual amino acid positions as
reported in UniProt entries, used by IMEx and UniProt. We also
found cases where mutations with little or no effect over
interaction outcome were not reported in the IMEx data set, a
result of early curation guidelines, which did not require the
annotation of a mutation unless an effect was clearly shown.
Additionally, UniProt and SKEMPI 2.0 report mutations for
which the actual evidence was originally generated in a
publication referenced in the one attached in the record.
According to IMEx guidelines, all mutation annotations must
be referred to the original publication. Finally, some annotations
were just missing in one or more of the resources for no obvious
reason, although we could attribute some cases to non-parseable
UniProt records. Full details of our manual assessment can be
found in Supplementary Data 1.
The IMEx Consortium is currently formed by 11 groups, each
one with their own area of interest, that have agreed to use the
same curation standards and data representation download
formats. All members of the consortium16–23 use the curation
platform provided by the IntAct team at EMBL-EBI. Figure 1e
shows the number of events annotated by each data resource.
Large databases such as IntAct, DIP and MINT, with an exclusive
focus on interaction data curation, have produced the majority of
the annotations, but a sizeable part of the data set has been
entered by other, domain-specific, members of the Consortium.
According to the IMEx schema and curation policy, interaction
evidence, rather than interacting pairs of molecules, is the focus of
the data representation. This results in the curation of multiple
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Fig. 1 IMEx mutations data set overview. a Number of annotations by effect type; b Increase of reported protein interactions involving wild type and
mutated proteins over time. Bars represent total number of PPIs reported each year (wild type proteins in gold, mutated proteins in blue). Lines represent
the cumulative sum of PPIs with mutated proteins, with the solid line representing the actual cumulative trend and the dashed line showing a projection for
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effect
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distinct pieces of evidence describing the same interacting pairs
and offers a way to weight how well characterized is a given
interacting group of molecules. It also enables us to capture
separate experiments where different sequence variants are tested
for their effect on an interaction. Most of the proteins in the data
set have a low number of associated mutations, with most
proteins having less than 15 annotations (Supplementary
Figure 2a) and 5 or less sequence changes (Supplementary
Figure 2b). There is a greater depth of information available for
human proteins, since the relative amount of human data vs other
species increases with the number of annotations per protein.
The IMEx evidence-centric curation model also makes it
possible to check whether the same mutation has been tested on
identical interacting molecules using different interaction detec-
tion methodologies (or by different research groups) and
whether the outcome of the mutations has been consistent in
all these experiments. In Fig. 1f we show that the majority of
the mutations have only been annotated once (tested in one
experiment only). In those cases where there have been multiple
instances of evidence testing, the results appear to be highly
consistent, with only a small number of cases identified for which
conflicting results have been reported. For 7212 cases where the
effect of a mutation on an interface was tested 2 or more times,
only 90 (1.3%) show different effects, and only 19 cases (0.3%)
reported antagonistic effects. We carefully checked antagonistic
cases and found that in 17 out of 19 cases, the reason for these
apparently contradictory results were mutant forms tested in
experimental setups that provide fundamentally different types of
information. The most common case is when the mutant and
wild-type versions of a protein were tested for enzymatic activity
and for binding in separate assays. For example, Bacillus subtilis
SufU C41A variant forms an hetero-tetramer with its potential
substrate SufS, but loses its sulfotransferase activity24. The
remaining 2 cases were genuine conflicts, caused by different
publications using similar experimental approaches, but reporting
different effects. A detailed overview of this comparison can be
found in Supplementary Data 2.
The vast majority of the data set refers to amino acid
substitutions, with a marginal amount of insertions and deletions
reported (only 65 deletion and 83 insertion annotations).
Figure 2a shows that arginine, leucine and serine are the most
frequently replaced residues, while histidine and methionine
residues are mutated less often (see Supplementary Figure 3a for a
more detailed view on specific replacements). Alanine is by far the
most frequently used residue for replacement (Fig. 2b), which is
probably reflective of the widespread use of alanine scanning25 to
identify residues critical for binding to other molecules, either
because they are found on the interacting interface or at an
allosteric binding site. When we checked the relative proportion
of the different mutation effects per replacing residue (Fig. 2c,
Supplementary Figure 3b), alanine replacements mostly associate
with deleterious effect on interactions. The dominance of
deleterious effects most probably reflects the authors of the
original study using alanine scanning to locate binding-related
residues.
Genomic variation and the IMEx mutations data set. In this era
of deep-sequencing genomics, there is a wealth of data concerning
nonsynonymous genomic variants. As discussed before, the
motivation behind the design of these experiments varies, and
only a fraction were specifically designed to systematically test
known variants vs reference (wild type) versions of the partici-
pant proteins5,26. Hence, we decided to explore how much cur-
rently available information for natural or disease-related
variation can be linked to the data set. Because of the strong
predominance of human data both in IMEx mutations and in
variation data sets, we decided to focus on human proteins only.
We used the EMBL-EBI Proteins API27 to access variation data
both manually annotated by and mapped to UniProtKB from
large-scale sequencing studies such as the 1000 Genomes28,
ExAC29 and COSMIC30 projects. We queried 8820 sequence
changes in 1990 human proteins, corresponding to 16,765 IMEx
mutation annotations (see Table 4 and Fig. 3). 29% (4804) of the
mutation annotations (Fig. 3a) and 12% (1073) of the sequence
changes (Fig. 3b) were fully mapped to natural variants. We also
checked cases in which there is a variant described in the same
position as a mutation reported in the IMEx data set, but the
amino acid change is different in the two data sets (positional
matches), and also those where mutations span more than one
residue and only some of the residue changes or positions are
matched in UniProtKB (partial matches). Sixteen percent (2671)
of the mutation annotations (Fig. 3a) and 16% (1415) of the
sequence changes (Fig. 3b) are positional or partial matches. The
biological significance of positional and partial mappings does not
go beyond stating that the region or position in question is
important for interaction and is variable. However, we believe this
information might be useful for researchers interested in
exploring specific regions in more detail.
We also checked how many of the mapped variant annotations
have been linked to disease according to UniProtKB. Disease
associations were complemented with data from the DisGeNET
Table 3 Resources reporting mutation effect over interaction
IMEx mutations data set UniProtKB mutagenesis
annotations
SKEMPI 2.0
Annotations 27,868 (16,861 human) 8620 (5265 human) 6108 (2743 human)
Sequence changes 14,647 (7955 human) 8297 (5043 human) 3126 (1724 human)
Publications 4182 3344 237
Species 297 93 55
Description of variation effect Structured controlled vocabulary Free text, controlled syntax Structured tabular
representation
Referenced to original publication Yes Yes Yes
Interaction experimental context Fully captured Not captured Only kinetics
Kinetic parameters associated
with variation
Yes, if available (very few cases) No Yes
Up-todate with proteome builds Yes Yes No (referenced to PDB)
Active curation Yes Yes Uncertain (last update
2018)
Accessibility Table accessible through ftp, website, standard formats for
interaction representation
UniProt ftp, website,
Proteins API
Website, downloadable
CSV table
Website www.ebi.ac.uk/intact/resources/datasets#mutationDs www.uniprot.org https://life.bsc.es/pid/
skempi2/
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database31. There were disease-associated variants for 42% (840)
of the proteins queried, with a median value of 4 disease variants
mapped per protein. As seen in Table 4, 20% (3432) of IMEx
mutation annotations have been tagged as related to disease, with
over 900 known disease variants represented in the data set.
UniProtKB derives disease annotations for variants from both
manual curation32 and imports of cross-referenced data from
ClinVar33 via Ensembl34, while DisGeNET also includes variants
from the GWAS Catalog35, and from text-mining the scientific
literature. Figure 3c shows the distribution of the variant
associations for different disease classes using the Medical Subject
Headings (MeSH)36 classification. A detailed list of these
mutation annotation-disease associations can be found in
Supplementary Data 3.
We then checked if the proportion of disease-related annota-
tions in IMEx varies depending on the reported effect on
interaction. As seen in Fig. 3d, e, disease-related mutations tend
to have mostly deleterious effects on interaction outcome, but we
could also map a considerable number of annotations where there
was an increase or even gain-of-function in terms of binding (411
annotations representing 116 variants). When we look at
mutation recurrence in different types of cancer as extracted
from cBioPortal37, mutations strengthening interactions seem to
have both statistically higher recurrence values and a higher
proportion of mutations with extremely high recurrence in cancer
data sets (Fig. 3f, g).
Computational predictions and literature curation. There is
currently a variety of computational tools used to annotate var-
iation data sets38. These tools can report the effect of variation on
protein function, folding or binding, usually based almost
exclusively on sequence or structural data, or can also report
genome-derived parameters such as allele frequencies or con-
servation scores. We wanted to study how variation annotations
provided by these tools align with experimental effect over
interaction as reported in the literature.
For this purpose, we used mutfunc (www.mutfunc.com)39, a
database reporting the effect of almost any possible mutation on
protein stability, interaction interfaces, post-translational
0
1000
2000
3000
4000
R H K D E S T N Q A V I L M F Y W C G P
Original residue
N
um
be
r o
f
re
pl
ac
em
en
ts
0
5000
10,000
15,000
R H K D E S T N Q A V I L M F Y W C G P
Resulting residue
N
um
be
r o
f
re
pl
ac
em
en
ts
0.00
0.25
0.50
0.75
1.00
R H K D E S T N Q A V I L M F Y W C G P
Resulting residue
Ef
fe
ct
 ty
pe
 p
ro
po
rti
on
Mutation
effect
Decreasing
Disrupting
Increasing
Causing
No effect
Undefined
a
b
c
Fig. 2 Amino acid replacement frequencies in the full data set. a Replacement frequencies by original residue; b Replacement frequencies by resulting
residue; c Normalized frequencies of resulting sequences by mutation effect over the interaction. Substitutions with non-standard amino acids and
deletions are not shown for simplicity. Source data are provided as a Source Data file
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-07709-6
6 NATURE COMMUNICATIONS |           (2019) 10:10 | https://doi.org/10.1038/s41467-018-07709-6 | www.nature.com/naturecommunications
Table 4 Variant mapping summary
Variant record type Proteins annotated
(1990 searched)
UniProtKB variants mapped to
IMEx annotations
IMEx annotations mapped to
UniProtKB variants
Full matches Cumulative with partial/
positional matches
Full matches Cumulative with partial/
positional matches
Natural variant 1948 1073 2488 4804 7475
Disease variant 840 732 877 3432 3804
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Fig. 3 Genomic variation and disease annotations in the IMEx mutations data set. a Mapping IMEx mutation annotations to UniProtKB human variants;
b Mapping UniProtKB human variants to IMEx-reported sequence changes; c Distribution of IMEx mutation annotations associated with selected MeSH
disease classes (see Supplementary Data 3 for a complete list of disease-mutation associations). Bars are coloured according to the type of mapping
between disease variants and IMEx mutation annotations (full match: blue, partial/positional match: grey); d IMEx mutation annotations by effect type and
their relation to disease; e IMEx mutation sequence changes by effect type and their relation to disease; f cBioPortal recurrence scores for mutations
grouped by effect type. p-values calculated with one-sided Wilcoxon test are indicated (decreasing vs no effect W= 582.5; increasing vs no effect W=
521.5); g Proportion of highly recurrent cancer variants according to cBioPortal by effect type. p-values calculated with Fisher exact test are indicated.
Source data are provided as a Source Data file
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modifications, protein translation, conserved regions, and reg-
ulatory regions. It hosts pre-computed variation effect data
derived from established resources such as SIFT40, Interac-
tome3D41 or FoldX42.
We first examined the predicted destabilization effect of
mutations on structural models of protein–protein interfaces,
dividing them by the literature-reported effect. As can be seen in
Fig. 4a, mutations with a ‘decreasing’ and especially a ‘disrupting’
effect on interactions had a significantly higher predicted
destabilization effect than those with no effect, a difference that
was not seen in mutations that would strengthen or even cause an
interaction. These deleterious groups also contained a signifi-
cantly higher proportion of mutations predicted to be very
destabilizing for interfaces (Fig. 4b).
We next studied genome-derived parameters that are useful to
study variation, such as residue conservation or natural allele
frequencies. The experimentally observed impact on binding
stability that we report in our data set may also be reflected on
these parameters. This assumption was partially confirmed using
three independent measurements. Firstly, we used the ‘sorting
intolerant from tolerant’ (SIFT) method40, observing that the
proportion of variants with low tolerance scores was significantly
higher in all groups where an effect was reported vs the ‘no effect’
reference (Fig. 4c). Secondly, we also checked allele frequencies as
derived from ExAC data. Again, mutations with a reported effect
seemed to have significantly lower allele frequencies (Fig. 4d) and
a higher proportion of alleles with extremely low frequencies
(Fig. 4e) than those reported to have no effect over interaction.
Finally, we used PolyPhen243, a missense mutation effect
prediction algorithm that uses a naive Bayes classifier based on
both sequence-based and structure-based predictive features. In
this case, mutations predicted to be deleterious by PolyPhen2
were significantly enriched in the ‘decreasing’ and ‘disrupting’
effect groups vs those with ‘no effect’ (Fig. 4f).
The interaction-perturbing effects reported in the IMEx data
set can be caused by modifying overall protein structure or by
alteration of binding interfaces. We can determine if the
mutations reported fall within sequence regions associated with
binding using both computational predictions and literature-
reported experimental data. We obtained predicted interfaces,
based on available structural data, from Interactome3D41.
Literature-curated interfaces were inferred from IMEx records
that contained participant features of the ‘binding-associated
region’ (MI:0117) branch. These represent experiments where the
authors have tested fragment constructs in an attempt to find
sequence regions that are critical for binding, although they may
not necessarily represent the actual binding surface. As seen in
Fig. 4g, h, most of the mutations fall within predicted or curated
interfaces. The proportion of mutations having an effect over the
interaction seems to be higher in binding interfaces, both
predicted and inferred from IMEx curation. Disease-associated
variants seem to show the same pattern (Supplementary
Figure 4a, b). Thus, the majority of the variants reported to have
effects on protein interactions (68%) can be linked to perturba-
tions inside binding regions, with a smaller proportion of variants
(32%) potentially representing systemic or allosteric effects
influencing interactions.
Phosphorylation and mutations in interactions. Post-
translational modifications (PTMs) can be regarded as chemical
switches with the potential to influence protein interactions44. We
explored whether mutations with reported effects in our data set
are enriched in known sites of protein modification, focusing on
phosphorylation in human proteins as the best characterized
PTM data set. Using phosphosite annotations from
PhosphoSitePlus®45, we found that decreasing, disrupting and
increasing mutations are indeed enriched in annotated phos-
phosites (Fig. 5a). Specific amino acid substitutions are com-
monly used to either disrupt a phosphosite (phospho-disrupting
mutations, where serine, threonine or tyrosine are replaced with
alanine, glycine, valine or phenylalanine) or to simulate it
(phospho-mimetic mutations, with the same amino acids
replaced by glutamic or aspartic acid). Looking at these sub-
stitutions specifically, we can see that phosphosite-disrupting
mutations account for the majority of the overlap with annotated
phosphosites and are again enriched for decreasing, disrupting
and increasing effects (Fig. 5b). Phospho-mimetic mutations are
significantly enriched only when they have an increasing effect
over interaction (Fig. 5c).
Literature bias in the IMEx mutations data set. IMEx databases
have a wide scope when selecting publications for curation and it
is reasonable to assume that the proteins in this data set are
representative of the interaction data that has been explored in the
literature. Socially driven, literature bias is a well-known phe-
nomenon previously reported for literature-curated data sets26,46,
so we decided to explore to what extent it affects the data set.
First, we checked whether the number of annotations and
variants found in the data set and the number of publications in
which the affected protein is reported are correlated. As seen in
Fig. 6a, b, the data set contains examples of both heavily researched
proteins with a low number of annotations and variants and vice
versa. If we fit linear models between the number of annotations/
variants and number of publications in which a protein is reported
we find a slight positive correlation, especially in the case of
disease-related variants. This observation is compatible with
socially-induced bias, with known disease-related proteins and
variants being more often reported in the literature.
Then we set out to find if the proteins represented in the
mutations data set are involved in distinctive pathways vs all
proteins for which IMEx has interaction information. To avoid
database-specific biases we performed annotation enrichment
analysis using PathDIP (http://ophid.utoronto.ca/pathDIP), an
analysis tool that integrates information from 20 source data-
bases47. Human proteins were divided in different sets depending
on the effect reported for their mutations and their pathway
annotation enrichment was calculated using all the human
proteins in IMEx as background. Pathways obtained from these
sets have substantial overlap (Fig. 6c, 694 pathways). These results
suggest that the proteins whose mutation effect on interactions
have been collected in this data set may be biased, possibly due to
specific interest of the researchers exploring variation influence
on molecular interactions. Specifically, in the group of mutations
that show an effect on interactions, pathways related to the
immune system, signalling, disease and cell cycle control ranked
on the top (Supplementary Figure 5, see Supplementary Data 4
and 5 for full details), with little difference between effect
categories. There seems to be a predominance of cancer-related
pathways, with representatives in both the ‘disease’ and the
‘signalling’ categories, which agrees with the observation reported
in Fig. 6b that the literature is biased towards disease-related
variants.
Discussion
Here we present a unique resource containing experimental,
publicly available information about the impact of sequence
changes on specific protein–protein interaction outcomes. This is
a direct result of the IMEx Consortium full-detail curation poli-
cies and represents an example of how expert curation, resulting
in structured and standardized representations, is required in
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Fig. 4 Computational annotations and the IMEx mutations data set. a Interaction interface disruption as predicted with FoldX, by mutation effect type.
Indicated p-values calculated with Wilcoxon test (decreasing vs no effect W= 25,100; disrupting vs no effect W= 24,411); b Proportion of highly
disruptive variants by mutation effect type; c Proportion of low tolerance residue positions according to the SIFT, by mutation effect type; d ExAC-extracted
allele frequencies for mutations represented in the IMEx data set, by mutation effect type; e Low frequency variants, by mutation effect type. Indicated
p-values calculated with Wilcoxon test (decreasing vs no effect W= 1841.5; disrupting vs no effect W= 2389.5; increasing vs no effect W= 645);
f Proportion of deleterious substitutions according to Polyphen2, by mutation effect type; g Number of mutation annotations located in binding interfaces
(curated and predicted), by effect; h Normalized frequencies of mutation annotations reporting effects over interactions or not and their localization in
binding interfaces. p-values indicated in panels b, c, d and f were calculated with Fisher exact test. Source data are provided as a Source Data file
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order to make the most of published experimental results. In
comparison to similar, pre-existing data sets recording variation
influence over interactions, this resource represents a leap for-
ward in depth, size and scope (Table 3). A previous, relatively
small study48 reported a curated list of about 100 mutations
influencing interactions. Despite obvious limitations due to its
size, this was used as benchmark in a study investigating the link
between disease-related variation and interaction interfaces1,
showing the applied potential of this type of data. The curation
infrastructure and practices of the IMEx Consortium will enable
the capture of data from a growing number of deep-mutagenesis
interaction studies, where hundreds if not thousands of single
amino acid changes over the whole length of a protein sequence
are explored for their influence on interactions49. New studies are
appearing in which the complex relationship between genetic and
protein interactions is explored50. These epistatic relations can
potentially be represented in the PSI-MI data model and the
curators in the IMEx Consortium are exploring ways to enable
their annotation.
We have also acknowledged the social biases inherent to any
literature-based resource in our data set, although it is difficult to
ascertain its extent. Alanine scanning features prominently as a
commonly used technique (Fig. 2b) and may represent amino
acid changes that will never be seen in nature due to evolutionary
constraints or simply because they would require extensive
sequence alteration at the DNA level, but remains an invaluable
source of information, identifying key binding-related positions.
For the human sub-section of the data set, disease-related variants
and proteins are possibly over-represented (Fig. 3b, c, Supple-
mentary Figure 5) and have been preferentially selected for bio-
curation over non-disease-related proteins (Supplementary
Figure 2a). Interestingly, we report over 100 disease-related var-
iants described in the literature to either cause or increase existing
interactions (Fig. 3d, e), some of which are found to be highly
recurrent in cancer according to cBioPortal51. This contrasts with
the findings reported by Sahni et al.5, where only two cases of
gain-of-interaction mutations were found in a systematic
screening for disease-related mutations and their effect on
interactions using yeast two-hybrid technology. Although
interaction decreasing/disrupting effects were much more fre-
quently reported, this highlights how gain-of-interaction
mechanisms could play a significant role in disease pathogen-
esis, especially in cancer.
We have also explored mutations that mimic or disrupt known
phosphorylation sites, finding enrichment in mutations with
reported effects. Phosphosite-disrupting mutations pre-
dominantly show detrimental effects on protein interactions, and
phosphosite-mimetic mutations have both detrimental and
increasing effects (Fig. 5). These results are consistent with
phosphorylation being regarded as a molecular switch influencing
binding function.
Analysis of variation is a fundamental tool in basic and clinical
research, with direct application in the clinic through transla-
tional genomics. Variation effects are explored mainly through
statistical analysis of large population data sets, GWAS studies, or
by quantitative analysis of its influence on expression via iden-
tification of eQTLs. However, in order to unravel the mechanisms
behind detected effects, it is key to explore how molecular
interactions are affected52. Currently, most of the mechanistic
insight into variation effects is generated by computational
annotation and predictions, using tools that are based on rela-
tively small reference sets, generally based on structural data. As
an example, the widely used FoldX algorithm is generated from
protein complex structures and has been tested against a library
of 1008 mutants42. Our current data set already provides inter-
action effects for over 10 times more individual variants and is
not limited to structural data. The wide scope of experimental
setups represented (Fig. 1c) allows the capture of effects on
proteins and protein regions that might be intrinsically non-
structured53. We show that the data set gives a currently
unparalleled and representative overview about which residues
are key for protein interactions, with the results being in good
accordance with commonly used variant annotators (Fig. 4).
IMEx curation practices originally did not enforce capturing
sequence changes that had no effect over interaction outcome, but
as a result of consultations with tool developers and data users
this policy has been amended and the data set now features a
growing number of mutations with no effect that can be used as a
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training negative set for the development of computational
annotation tools.
The IMEx mutations data set represents both a reference
source for direct, literature-based variant characterization and a
unique benchmark that can be used to further refine computa-
tional variant effect annotators. We will continue to expand the
data set and improve its accessibility for users, as a part of IMEx
global mission of ensuring data representation and re-use.
Methods
Source data. All analysis was performed using the September 2017 version of the
IMEx mutations data set, which can be directly downloaded from ftp://ftp.ebi.ac.
uk/pub/databases/intact/2017-09-02/various/mutations.tsv.
Software and packages used. The quality control pipeline for mutation anno-
tations was developed and integrated within the production code used in the IntAct
database. The code is written in Java and makes use of the Hibernate and Spring
frameworks for interaction with the core SQL database and application imple-
mentation. Specific implementation details are available upon request. Statistical
analysis, plots, mutation re-annotation checks and mappings were performed using
the R programming language54 through the RStudio programming suite55. The
following R packages were used in the study: data.table, dplyr, ggplot2, ggpubr,
gridExtra, gsubfn, httr, jsonlite, plyr, RCurl, reshape2, scales, seqinr, splitstack-
shape, XML, Biostrings, and biomaRt.
Curation practices. Data has been produced through manual literature curation
following the IMEx Consortium curation guidelines11, which can be explored in
detail on the Consortium’s website: www.imexconsortium.org/curation. Briefly,
every publication reviewed was curated for the entirety of the interaction data it
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contained, representing each experimental piece of evidence as a separate record.
Full details of constructs used were registered and every entry was reviewed by at
least two independent curators for quality control.
Mutations re-annotation effort. After the development of PSI-XML3.0 and the
‘resulting sequence’ field in the IMEx schemas to capture amino acid change in
participant features of the type ‘mutation (MI:0118)’ and children, it was necessary
to populate the field with legacy data from the participant feature short label. This
free-text, manually-entered field was prone to contain typographical errors and was
difficult to keep updated. Curators used a set of simple rules to depict amino acid
substitution, deletions and insertions. As a first step towards populating the
‘resulting sequence’ field, we wrote ad hoc parsing scripts to evaluate and extract
the information stored in the short labels. Several rounds of corrections took place
until the data set got to its current state. Of the 27,868 records of the data set,
20,161 had to be corrected, with around 2000 of them manually corrected. There
are still about 2500 records for which no fix was possible without fully amending
the original entry. These have been left out of the data set until being revisited by
an IMEx curator in due course. An automated quality control pipeline has been put
in place to handle newly-created entries and future changes in UniProtKB (details
in Supplementary Information section ‘Initial re-curation of mutation data in
IMEx’). Finally, we have also adapted the participant feature short labels to the
Human Genome Variation Society (HGVS) recommendations for variant anno-
tation56, which can be accessed at http://varnomen.hgvs.org/recommendations/
protein/.
IMEx, UniProt and SKEMPI 2.0 mutation annotations comparison. The latest
version of the SKEMPI 2.0 database was downloaded in July 2018 from https://life.
bsc.es/pid/skempi2/database/download/. The entries were parsed and the PDB
REST API was used to map the proteins in the PDB records to UniProt accession
numbers in order to enable comparison. Chain information was used to ascertain
the identity of the individual proteins. Cases where more than one protein was
reported by chain, as well as unmapped entries, were discarded from further
analysis. Finally, effect types were classified in two categories: ‘loss’ and ‘gain’ of
binding function. In order to classify the annotation in one of these two categories,
the affinity values for the mutant version of the sequence were normalized in
relation with the wild type form. Fold changes over and under 50% with respect of
the wild type were annotated as ‘gain’ or ‘loss’, respectively. Smaller fold changes
were qualified as ‘no effect’. UniProt mutagenesis annotations were obtained on 29
July 2018 parsing the UniProt webservice XML output using a Python script kindly
provided by Luz García-Alonso. Since interacting partners are only identified with
gene symbols in UniProt annotations, their precise identity could not be ascer-
tained for a number of records, which were discarded for further analysis. The
effects reported in the annotations were simplified and qualified as simple ‘loss’ and
‘gain’ of binding function. IMEx mutation types were simplified accordingly to
allow consistent comparison of mutation effects among data sets.
Assessment of conflicting mutation annotations. A mutation was defined as
‘conflicting’ when a sequence variant, tested against the same interacting partners,
was annotated for effects that are directly antagonistic (e.g. ‘disrupting’ vs
‘increasing’). Different proteoforms of the same reference protein were considered
as different interacting partners (e.g. a phosphorylated protein was considered
different from its non-phosphorylated form). When different effects were reported
but were not directly antagonistic the mutation was considered to be ‘consistent’ if
all effects went in the same direction (e.g. ‘disrupting’ and ‘decreasing’) or ‘mild
conflict’ if most went in the same direction and the rest were annotated as having
‘no effect’ (e.g. ‘decreasing’ and ‘no effect’).
Mapping IMEx mutations to UniProtKB and the genome. UniProtKB accessions
for human proteins were extracted from the IMEx mutations data set, retaining
isoform identifiers, and used to query the EMBL-EBI Protein API27. The API’s
‘variation’ method was used to extract large-scale variation annotation from
UniProtKB, regardless of its origin. Annotations extracted through this method
were then mapped to the IMEx mutations data set using UniProtKB accession,
sequence position and resulting amino acid for ‘full’ mappings and only Uni-
ProtKB accession and position for ‘positional’ mappings. Cases where the IMEx-
reported mutation spans more than one amino acid position were split into
individual substitutions and only labelled as ‘full’ matches if every individual
position matches an annotation in UniProtKB. Otherwise, they were considered
‘partial’ mappings. Disease annotations were extracted from the API’s output,
along with rsIDs. These rsIDs were then used in DisGeNET to search for additional
disease annotations that were brought in as well. The diseases were mapped to their
corresponding MeSH disease classes using the cross-references provided by the
Unified Medical Language System (UMLS) Metathesaurus (version 2017AB). In
the cases in which cross-references to MeSH were not available, we manually
assigned a parent, for example, Sporadic Breast Carcinoma was mapped to Breast
Carcinoma. This allowed to map 98.5 and 93% of the diseases in UniProt and
DisGeNET, respectively. The following MeSH disease classes were discarded
because they were deemed uninformative or not appropriate for the analysis in
hand: ‘pathological conditions, signs and symptoms’, ‘occupational diseases’ and
‘animal diseases’.
Predicting impact on protein interaction interfaces. Experimental and homol-
ogy modelled structures for protein interactions were obtained from the Inter-
actome3D database41. Relative solvent accessibility (RSA) for all residue atoms was
computed using NACCESS57 for proteins individually and in the interaction
complex. Interface residues were defined as those with any change in RSA. The
impact of a variant on interface stability was computed using FoldX v.4.0. All
binary interface structures were repaired using the RepairPDB command, with
default parameters. The Pssm command was then used to predict ΔG with num-
berOfRuns= 5. This performed the mutation multiple times with variable rotamer
configurations, to ensure the algorithm achieved convergence. The average ΔG of
all runs was computed and the ΔΔG was computed as the difference between the
wild type and mutant, providing a predictive estimate of how destabilising the
mutant was to the interaction interface.
Predicting variant functional impact with SIFT and PolyPhen2. In order to
calculate SIFT scores, all protein alignments were built against UniRef5058, using
the seqs_chosen_via_median_info.csh script in SIFT 5.1.159. The siftr R package
(https://github.com/omarwagih/siftr) was used to generate SIFT scores with
parameters ic_thresh= 3.25 and residue_thresh= 2. PolyPhen2 scores were
obtained from http://genetics.bwh.harvard.edu/pph2/bgi.shtml using the batch
query tool on 6 August 2018. The GRCh37/hg19 genome assembly and the
HumDiv classifier model were used for considering missense annotations against
canonical transcripts only.
Allele frequencies. A total of 3,198,692 coding variants in H. sapiens for over
65,000 individuals was collected from the ExAC Consortium29 in the ANNO-
VAR60 output format along with corresponding adjusted allele frequencies.
Ensembl transcript positions were mapped to UniProt by performing Needleman-
Wunsch global alignment of translated Ensembl transcript sequences against the
UniProt sequence using the pairwiseAlignment function in the Biostrings R
package. The mapping between Ensembl transcript IDs (v81) and UniProt acces-
sions was obtained from the biomaRt R package. In the case that multiple alleles
mapped to the sample single amino acid substitution, the one with the highest
adjusted allele frequency was retained.
Recurrence. Annotated somatic mutation recurrence data for 10,155 tumour
samples was obtained from the TCGA pan-cancer atlas data set downloaded from
cBioPortal v1.15.0 on 11/08/2018. The data set comprises 1,866,976 missense
variants mapped to UniProt and belonging to 33 tumour types.
Mapping variants to interaction interfaces. Predicted interface and accessibility
coordinates were obtained from Interactome3D. Curated interfaces were extracted
from IntAct by selecting participant features under the PSI-MI term ‘binding-
associated region’ (MI:0117). Only human proteins for which accessibilities were
calculated directly from structural data in Interactome3D were selected for this
analysis, modelled structures were excluded.
Mapping mutations and phosphosites. Phosphosite data was downloaded from
PhosphositePlus® (www.phosphosite.org) on 02/07/2018. All phosphosite anno-
tations for human proteins were considered for the analysis and mapped to our
data set using provided UniProt coordinates. Only mutations on serine, threonine
or tyrosine residues were used for the comparisons.
Estimating literature bias. We used the NCBI ‘geneID2pubmed’ table, accessible
at ftp://ftp.ncbi.nih.gov/gene/DATA/gene2pubmed.gz, to estimate how many
papers were associated to individual proteins in the IMEx mutations data set. Only
human proteins were considered. Entrez GeneIDs were mapped to UniProtKB
accessions using UniProt’s website REST API mapping service as described at
www.uniprot.org/help/api_idmapping.
Pathway enrichment analysis using PathDIP. Pathway enrichment was per-
formed using mutated PPIs (i.e. mutated protein+ partner) of a given mutation
type (causing, disrupting, etc.) and pathDIP 2.5 pathways (considering only core
pathway, http://ophid.utoronto.ca/pathDIP47). We considered whole IntAct
human PPIs as a background for enrichment analysis (downloaded 24 March
2018). For pathways overlap Venny 2.1.0 (http://bioinfogp.cnb.csic.es/tools/venny)
was used and Wordle (www.wordle.net) was used to prepare word clouds from
enriched pathway titles.
Code availability. The code and mappings used for analysis are available upon
request.
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Data availability
The IMEx mutations data set is open access and fully available at www.ebi.ac.uk/
intact/resources/datasets#mutationDs under an open Creative Commons Attribu-
tion 4.0 International licence (CC-BY4.0), like all IMEx data. All additional data
used in this publication is open access and sources are cited where appropriate.
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